Healthcare - Biotechnology - NASDAQ - US
$ 0.0001
0 %
$ 5.45 K
Market Cap
0.0
P/E
CASH FLOW STATEMENT
-28.9 M
OPERATING CASH FLOW
-1.18 M
INVESTING CASH FLOW
5.28 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Better Therapeutics, Inc.
| Net Income | -39.8 M |
| Depreciation & Amortization | 2.73 M |
| Capital Expenditures | -1.18 M |
| Stock-Based Compensation | 1.82 M |
| Change in Working Capital | 6.27 M |
| Others | 4.76 M |
| Free Cash Flow | -30.1 M |
Cash Flow
Millions
| Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | |
|---|---|---|---|---|
| OPERATING CASH FLOW | ||||
| Net Income | (39.8) | (40.3) | (6.4) | (5.8) |
| Depreciation & Amortization | 2.7 | 1.6 | 75 K | 72 K |
| Deferred Income Tax | 0 | (0.2) | 0.2 | 505 |
| Stock Based Compensation | 1.8 | 0.6 | 0.2 | 84 K |
| Other Operating Activities | 9 K | 9.7 | (0.2) | 505 |
| Change in Working Capital | 6.3 | (2.3) | 0.3 | (0.6) |
| Cash From Operations | (28.9) | (30.8) | (5.8) | (6.2) |
| INVESTING CASH FLOW | ||||
| Capital Expenditures | (1.2) | (1.1) | (2.3) | (2.7) |
| Other Items | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (1.2) | (1.1) | (2.3) | (2.7) |
| FINANCING CASH FLOW | ||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 5.0 | 28.7 | 0 | 5.0 |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0.3 | 43.7 | 7.4 | 3.7 |
| Cash From Financing Activities | 5.3 | 72.3 K | 7.4 | 8.7 |
| CHANGE IN CASH | ||||
| Net Change In Cash | (24.8) | 40.4 | (0.6) | (0.3) |
| FREE CASH FLOW | ||||
| Free Cash Flow | (30.1) | (31.9) | (8.1) | (9.0) |